High HIV, HPV, and STI Prevalence Among Young Western Cape, South African Women

Giuliano, Anna R.; Botha, Matthys H.; Zeier, M; Abrahamsen, Martha; Glashoff, Richard H.; Laan, Louvina E van der; Papenfuss, Mary; Engelbrecht, Susan; Loeff, Maarten F. Schim van der; Sudenga, Staci L.; Torres, B. Nelson; Kipping, Siegfried; Taylor, Douglas

doi:10.1097/qai.0000000000000425

Cited by 32 publications

(41 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that 71% of our study participants regardless of study arm had at least one HPV type at enrollment and 22% were positive for at least one of the HPV types in 4-valent vaccine. [8] This prevalence of any HPV type of 71% is comparable to HPV prevalence observed among female sex workers and HIV-positive women in Africa (39%-75%). [13] HPV16 point and period prevalence among women in our cohort was 15% and 17% respectively, comparable to only one other cohort of HIV-negative women studied in Cape Town, South Africa (16%).…”

Section: Discussionmentioning

confidence: 60%

“…Overall 12% of participants had a low grade squamous intraepithelial lesion (LSIL) and one participant had a high grade squamous intraepithelial lesion (HSIL) at enrollment. [8] This low prevalence may reflect that the infections detected were relatively recently acquired, not allowing sufficient infection duration for us to observe progression to lesions, especially HSIL.…”

Section: Discussionmentioning

confidence: 99%

“…A full description of study procedures and conduct of the trial has been published elsewhere. [8] Briefly, women aged 16-24 that were HIV-negative and non-pregnant were enrolled in a Phase II randomized controlled trial of Gardasil (4-valent HPV (4vHPV) vaccine) vs. placebo (saline).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial

Sudenga

Torres

Botha

et al. 2016

Journal of Infection

Self Cite

View full text Add to dashboard Cite

Objective The objective of this analysis was to assess human papillomavirus (HPV) infection persistence and incidence 7-months post-enrollment by HPV vaccine study arm (vaccine or placebo). Methods HIV-negative, sexually active women aged 16-24 years in the Western Cape, South Africa, were enrolled in the EVRI Trial and were randomized to receive 4-valent HPV vaccine or placebo. Cervical specimens were collected at enrollment and at the 7-month visit and were genotyped for HPV. HPV prevalence, persistence, and incidence were calculated. Prevalence ratios and odds ratios were calculated to assess factors associated with a prevalent and incident HPV infection. Results HPV incidence rates were marginally higher for the placebo group (n=163) compared to the vaccine group (n=169). A large proportion of the prevalent high risk (HR-HPV) HPV types (49%) persisted over the 7-month period in both arms. Prevalent HR-HPV infection was significantly associated with a prevalent gonorrhea infection and detection of Herpes simplex type 2 antibodies. Incident HR-HPV infection was significantly associated with abnormal cervical cytology at enrollment and younger age. Conclusions Women living in geographic areas, such as southern Africa, at high-risk for HPV need to receive HPV vaccination at a very young age to maximally prevent infection and subsequent disease.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial

Sudenga

Torres

Botha

et al. 2016

Journal of Infection

Self Cite

View full text Add to dashboard Cite

show abstract

“…All of the women that received the 4vHPV vaccine seroconverted to all four HPV genotypes. Women in this cohort not only have a high seroprevalence to HPV, but also have a high prevalence of HPV infections at the cervix (71%), other sexual transmitted infections with 33% having a chlamydia infection and 47% seropositive for Herpes Simplex Virus-2, and 12% having abnormal cervical cytology at trial enrollment [15]. HPV vaccines are prophylactic and need to be administered prior to sexual debut to have the greatest effectiveness in preventing disease.…”

Section: Discussionmentioning

confidence: 99%

“…A full description of study procedures and conduct of the trial has been published elsewhere [15]. Briefly, women aged 16–24 years that were HIV-negative and non-pregnant were randomized 1:1 in a Phase II controlled trial of Gardasil (4-valent HPV (4vHPV) vaccine) vs. placebo (saline).…”

Section: Methodsmentioning

confidence: 99%

HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial

Sudenga

Torres

Botha

et al. 2017

Papillomavirus Research

Self Cite

View full text Add to dashboard Cite

BackgroundHPV antibodies are a marker of past exposure to the virus. Our objective was to assess HPV serostatus pre- and post-vaccination among HIV-negative women.MethodsWomen aged 16–24 years old were randomized in a placebo controlled trial utilizing the 4-valent HPV (4vHPV) vaccine (NCT01489527, clinicaltrials.gov). Participants (n=389) received the 4vHPV vaccine or placebo following a three dose schedule. Sera were collected at Day 1 and Month 7 for assessment of HPV 6, 11, 16, and 18 neutralizing antibody levels using a multiplex competitive Luminex immunoassay (Merck) based on detecting the L1 capsid antigen for each HPV type.ResultsSeroprevalence was 73% for HPV6, 47% for HPV11, 33% for HPV16, and 44% for HPV18. Seroprevalence for any HPV type did not significantly differ by age or lifetime number of partners. The majority of participants (64%) had two or more 4vHPV antibodies present at enrollment and 12% had antibodies to all four. Among women in the vaccine arm, those that were seropositive for HPV16 at enrollment had higher titers at month 7 compared to women that were seronegative for HPV16 at enrollment; this trend holds for the other HPV types as well. Seroconversion among baseline seronegative participants in the placebo group ranged from 5% for HPV16 to 23% for HPV6.ConclusionHPV seroprevalence was high in this population, emphasizing the need to vaccinate prior to sexual debut.

show abstract

Adolescent Sexting and Risky Sexual Behaviours in Zimbabwe: A Cross-Sectional Study

Marume

Maradzika

January

2018

Sexuality & Culture

View full text Add to dashboard Cite

High HIV, HPV, and STI Prevalence Among Young Western Cape, South African Women

Cited by 32 publications

References 42 publications

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial

HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial

Adolescent Sexting and Risky Sexual Behaviours in Zimbabwe: A Cross-Sectional Study

Contact Info

Product

Resources

About